NBS NEWZZZ $12M CASH FROM ERYE CLOSURE // NeoStem Closes

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2012 at 10:26 AM

[b]NBS > NEWZZZ $12M CASH FROM ERYE CLOSURE [/b]// NeoStem Closes Divestiture of Its Ownership Interest in Suzhou Erye

2012-11-13 09:08 ET - News Release

NEW YORK, Nov. 13, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE:NBS) ("NeoStem" or the "Company"), an emerging market leader in the fast growing cell therapy industry, today announced that the Company has completed the divestiture of its 51% ownership interest in Suzhou Erye Pharmaceutical Co. Ltd. ("Erye"), a China-based generic pharmaceutical company. The divestiture provides NeoStem with $12,280,000 in cash and removes from the Company's balance sheet over $30 million in short and long-term debt obligations. Erye also returns 1,040,000 shares representing approximately 0.7% of the Company's outstanding common stock, 1,170,000 stock options representing approximately 5.1% of the Company's outstanding options and 640,000 warrants to purchase common stock held by Erye representing approximately 1.1% of the Company's outstanding warrants.

"We are very pleased to have reached this significant milestone in our business," said Dr. Robin Smith, Chairman and CEO of NeoStem. "The Erye divestiture brings non-dilutive capital that bolsters our cash position in the United States, reduces legal and financial reporting expenditures, simplifies our financial statements and focuses our efforts exclusively on the rapidly growing cell therapy industry. The divestiture also paves the way for the Company to qualify for new funding through the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program which would support our pre-clinical development of VSELTM Technology. NeoStem will also be able to invest more resources into its cell therapy development and contract manufacturing activities."

About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy industry. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic product candidate, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSEL TM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we believe we are well positioned to succeed.

For more information on NeoStem, please visit www.neostem.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's or its partners' successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company's ability to successfully penetrate such markets and the market for its contract development and manufacturing ("CDMO") business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors, including but not limited to matters described under the "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company's other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

CONTACT: For more information, please contact:
Trout Group
Gitanjali Jain Ogawa, Vice President
Phone: +1-646-378-2949
Email: gogawa@troutgroup.com

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AppLovin Faces Serious Investor Lawsuit Deadline

Investors' Trust Shaken: The AppLovin Controversy Well, what do we have here? Another day, another hefty lawsuit coming down the pike. The spotlight’s on AppLovin Corporation (NASDAQ: APP), where the Hagens Berman law sharks are sniffing blood in the water over what they claim are federal securities law violations. The core of this legal storm swirls around AppLovin's...

Partner Joins Yardi ICN, Boosting Data Quality for Clients

Strategic Alliances in Real Estate Data When Partner Engineering and Science, Inc. says they're hooking up with the Yardi Independent Consultant Network (ICN), that's not just some boardroom handshake. It's a play that could shake up data services in the real estate game. Look, there's plenty of chatter about digitizing property management, but without killer data, those...

AI-Driven Software Growth Faces Profitability Hurdles

AI and Growth: A Tale of Two Strategies Is AI the superhero we’ve been waiting for, or just another fad? The KeyBanc Capital Markets' 2026 AI x Software Benchmark throws more questions into the ring than it answers. This benchmark isn't just numbers on a page; it's a pulse check on how AI is reshaping the software landscape. Seeing AI-native firms grow at a dizzying 34%...

DEEPBLUE's Panelized Systems Target Low-Rise Markets

Changing the Game in Low-Rise Construction Been around the block a few times and seen all sorts of hype in this industry, but what DEEPBLUE SMARTHOUSE is pushing sounds more like evolution than revolution for low-rise builds. They're leaning into this panelized building system like a boxer on the ropes—that's their strategy to keep things steady and predictable. The...

Black Bayou Kicks Off Major Gas Storage Build in Louisiana

Breaking Ground on a Massive Energy Undertaking Well, folks, Black Bayou's finally breaking ground on their colossal gas storage project in Cameron Parish, Louisiana. They're not just playing around—this thing's set to be a juggernaut, with an imposing 44.4 Bcf of working gas capacity nestled right on top of the Black Bayou salt dome. Talk about marking territory, huh?...

Decoding Arrest: Steps from Arraignment to Trial

Someone lands in handcuffs, and it's the start of a winding road through the justice system. We're talking about the stages you gotta navigate, explained by Criminal Law Attorney Tangi Carter. If you're anywhere near Hattiesburg, Mississippi, or quite frankly, have any eye on legal matters in your backyard, you know having a roadmap is pure gold. Arraignment: The...

Global Energy Storage Colloquium Sparks Collaboration

Setting the Stage for Energy Storage Breakthroughs Imagine a room bustling with brainpower, brimming with the promise of cleaner, more efficient energy. That's the scene at the inaugural Global Energy Storage Colloquium in Xiamen, where top-tier experts from all corners gathered to uncover what's next for energy storage. We're not just talking new gadgets but giant leaps...

Cemig and Huawei's Bold Network Leap: Power Up

Taking the Leap in Brazil's Power Grid In Brazil, energy distribution's a whole different beast, and boy, is it complicated! Cemig found out the hard way that relying on public networks was a risky bet. Consistently bad. With a measly 50% coverage in Brazil's vast lands, you're looking at a communications nightmare, especially in the back of beyond where grid faults could...

SciGround Launches: A Game-Changer in Research Verification

Unshackling Research Verification from the Model Folks, here's the big one—Licklider, Inc. from Tokyo lobbed a curveball with their new player in town: SciGround. This platform takes the reins on mathematically verifying AI-driven research, which is something you'll want to keep an eye on if you're at all interested in AI or research replication. Why SciGround Gets My...

Choosing Expert European Auto Repair: Key Insights

The Perks of Specialist Knowledge Ever get the feeling your local auto shop doesn't always cut it when your sleek BMW or classy Mercedes needs a tweak? You're not alone. Specifically, for those driving around Alpharetta, European vehicles demand not just routine check-ups but specialist hands. Much like how you wouldn't hand your luxury timepiece to the shop down the...